Amylin: The Pancreatic Peptide That Regulates Blood Sugar, Appetite, and More
Amylin is a 37-amino acid pancreatic hormone that regulates blood sugar and energy metabolism, with pramlintide already approved for diabetes and clinical potential for obesity treatment.
Quick Facts
What This Study Found
Amylin is a 37-amino acid peptide hormone co-secreted with insulin from pancreatic beta cells. Its receptors are unique multisubunit G protein-coupled receptors formed by combining a core receptor protein with receptor activity-modifying proteins (RAMPs), creating multiple receptor subtypes.
Key roles and findings from 25 years of research:
- Primary function: glucoregulation — amylin helps control blood sugar alongside insulin
- Appetite regulation: acts in circumventricular organs of the brain to reduce food intake
- Metabolic interactions: functionally interacts with cholecystokinin, leptin, and estradiol
- Additional effects: cardiovascular and bone actions have been reported
- Clinical use: pramlintide (amylin analog) is FDA-approved for type 1 and type 2 diabetes
- Obesity potential: clinical studies show amylin agonists promote weight loss, especially in combination therapy
Key Numbers
How They Did This
This is a comprehensive narrative review published in Pharmacological Reviews, covering the full scope of amylin research from its discovery as a hormone through 2015. It synthesizes findings from rodent studies, human clinical trials, and basic receptor pharmacology research.
Why This Research Matters
Amylin represents a critical piece of the metabolic puzzle that is often overshadowed by insulin. Understanding amylin has led to pramlintide (an FDA-approved diabetes treatment) and is now driving research into combination therapies for obesity. The recent success of amylin analog cagrilintide in combination with semaglutide (CagriSema) has renewed intense interest in this pathway.
The Bigger Picture
Amylin research has experienced a renaissance with the development of long-acting amylin analogs for obesity. This review captures the foundational science that made those developments possible. As combination metabolic therapies (like amylin + GLP-1) advance through clinical trials, understanding amylin's basic pharmacology becomes increasingly important for the next generation of weight management drugs.
What This Study Doesn't Tell Us
As a narrative review, it synthesizes existing research without generating new data. Published in 2015, it predates the recent surge in amylin analog development for obesity (particularly cagrilintide). Some of the clinical potential discussed was speculative at the time and has since been confirmed or refined by newer studies.
Questions This Raises
- ?How will long-acting amylin analogs like cagrilintide perform in large-scale obesity trials compared to GLP-1 drugs alone?
- ?What is the optimal combination partner for amylin agonists — GLP-1, leptin, or other metabolic hormones?
- ?Do amylin's effects on bone and the cardiovascular system become clinically relevant with chronic use of amylin-based drugs?
Trust & Context
- Key Stat:
- 25 years of research This review covers amylin's journey from discovery to FDA-approved diabetes treatment and emerging obesity applications
- Evidence Grade:
- This is a comprehensive narrative review in a top pharmacology journal. It summarizes evidence ranging from basic science to clinical trials, but does not present original data. The strength lies in its breadth and the stature of the publication venue.
- Study Age:
- Published in 2015, this review provides foundational knowledge about amylin. The field has advanced significantly since, particularly with the development of cagrilintide and CagriSema for obesity, but the basic pharmacology covered here remains current and relevant.
- Original Title:
- Amylin: Pharmacology, Physiology, and Clinical Potential.
- Published In:
- Pharmacological reviews, 67(3), 564-600 (2015)
- Authors:
- Hay, Debbie L(5), Chen, Steve, Lutz, Thomas A(3), Parkes, David G, Roth, Jonathan D
- Database ID:
- RPEP-02659
Evidence Hierarchy
Frequently Asked Questions
What is amylin and how does it differ from insulin?
Amylin is a 37-amino acid hormone released alongside insulin from the same pancreatic beta cells. While insulin directly lowers blood sugar by helping cells absorb glucose, amylin slows stomach emptying, suppresses glucagon release, and reduces appetite through brain signaling — complementary mechanisms that help control blood sugar from different angles.
Is there an amylin-based drug available?
Yes. Pramlintide (brand name Symlin) is an FDA-approved amylin analog used to treat type 1 and type 2 diabetes. Newer long-acting amylin analogs are in clinical development for obesity, including in combination with GLP-1 drugs.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-02659APA
Hay, Debbie L; Chen, Steve; Lutz, Thomas A; Parkes, David G; Roth, Jonathan D. (2015). Amylin: Pharmacology, Physiology, and Clinical Potential.. Pharmacological reviews, 67(3), 564-600. https://doi.org/10.1124/pr.115.010629
MLA
Hay, Debbie L, et al. "Amylin: Pharmacology, Physiology, and Clinical Potential.." Pharmacological reviews, 2015. https://doi.org/10.1124/pr.115.010629
RethinkPeptides
RethinkPeptides Research Database. "Amylin: Pharmacology, Physiology, and Clinical Potential." RPEP-02659. Retrieved from https://rethinkpeptides.com/research/hay-2015-amylin-pharmacology-physiology-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.